Home 2018-01-02T12:07:48+00:00

Science

Developing Therapeutics for Cancer and Rare Diseases

LAM Therapeutics develops precision therapeutics for cancer and rare diseases. Our aim is to accelerate drug development by deploying technologies including next-gen sequencing, genome editing, chemical genomics, and combinational drug screening, with deep learning to match clinical drugs to new indications. LAM has advanced three drugs into clinical trials: LAM-001 for lymphangioleiomyomatosis, LAM-002 for B-cell non-Hodgkin lymphoma, and LAM-003 for acute myeloid leukemia.

Approach

LAM’s virtuous circle strategy integrates patient data, AI, and next-generation sequencing. We test LAM drugs in clinical trials, and then analyze genomics and proteomics data to match drugs to patients. Our deep learning AI technology gets smarter with each patient treated and more data analyzed, which helps us select the most appropriate patients to treat.

Publications

ASH Poster

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

Wael A Harb, Catherine S Diefenbach, Nehal Lakhani, Sarah C Rutherford, Marshall T Schreeder, Stephen M. Ansell, Taimur Sher, David M Aboulafia, Jonathon B Cohen, Darrell Nix, Sean Landrette, Kate Flanders, Langdon L Miller, Henri Lichenstein and Jeremy S. Abramson

59th ASH Annual Meeting & Exposition

View poster

Blood cover

Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma

Sophia Gayle, Sean Landrette, Neil Beeharry, Chris Conrad, Marylens Hernandez, Paul Beckett, Shawn M. Ferguson, Talya Mandelkern, Meiling Zheng, Tian Xu, Jonathan Rothberg and Henri Lichenstein

Blood 2017 129:1768-1778

View publication
View supplemental methods, figures, and data

Autophagy cover

B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition

Sophia Gayle, Sean Landrette, Neil Beeharry, Chris Conrad, Marylens Hernandez, Paul Beckett, Shawn M. Ferguson, Talya Mandelkern, Meiling Zheng, Tian Xu, Jonathan Rothberg and Henri Lichenstein

AUTOPHAGY 2017, VOL. 13, NO. 6, 1–2

View publication

Toward autophagy-targeted therapy in lymphoma

Lapo Alinari

Blood 2017 129:1740-1742

View publication

LAM Logo Circle

Precision Medicine Programs

Accelerating discovery of medicines to change the lives of people we love

Our programs target lymphangioleimyomatosis, B-cell non-Hodgkin lymphoma and acute myeloid leukemia.

Clinical Trials

A clinical trial is a carefully supervised research study performed in humans before an investigational drug is available to the general public. Clinical trials play an important role in the development process of new drugs by providing data to evaluate a drug’s safety and efficacy. Anyone interested in participating in a clinical study should know as much as possible about the study and discuss any questions or concerns with their physician and healthcare providers in order to make an informed decision prior to enrolling in a clinical trial. Learn more about clinical trials.

Careers

LAM Therapeutics is a fully-funded startup dedicated to developing breakthrough therapeutics for the treatment of rare diseases and cancer.
Working with proprietary technologies, LAM Therapeutics is making a difference. The company is privately funded, allowing you to focus 100% on doing the best science of your life.
Join a world-class team in developing the next-generation of breakthrough drugs. LAM Therapeutics is seeking extraordinary gifted and driven scientists, with a track record of success developing, implementing and scaling up new technologies.

NOTE TO RECRUITERS

The Company does not accept resumes submitted by, or candidates referred from, external agencies by any means (including but not limited to via the Internet, email, fax, U.S. mail and/or verbal communications). Any third-party resume forwarded by such recruiters will be treated as a direct application and shall be deemed to be the property of the Company, and the Company reserves the right to contact the candidate directly and the recruiter will not receive any compensation from the Company.

About LAM Therapeutics

LAM is at the forefront of transforming how we match drugs to patients for best response. We call our strategy the ‘virtuous circle.’ We test LAM drugs in patients, and then analyze the data with genomics and proteomics. Our deep learning AI technology gets smarter with each patient treated and more data analyzed, which helps us select the most appropriate patients to treat.

Dr. Tian Xu, LAM co-founder

Our People

Henri Lichenstein

Henri Lichenstein, Ph.D.

President & CEO

Henri Lichenstein, Ph.D.

Henri Lichenstein is the President and CEO of LAM Therapeutics. Dr. Lichenstein has over 30 years of drug development experience at Amgen, CuraGen Corporation, Topotarget, and BioPontis Alliance, and has led numerous successful drug development efforts resulting in the advancement of therapeutics from discovery into clinical development. At Topotarget and CuraGen Corporation, Dr. Lichenstein led the global pre- and clinical development of the histone deacetylase inhibitor, belinostat, in…

View full profile >
Tian Xu

Tian Xu, Ph. D.

Scientific Advisory Board

Tian Xu, Ph. D.

Tian Xu serves on LAM Therapeutics Scientific Advisory Board. Dr. Xu is Professor and Vice Chair of Genetics at Yale University School of Medicine and a Howard Hughes Medical Institute Investigator. He also serves as Director of the Institute of Developmental Biology and Molecular Medicine at Fudan University in Shanghai. He was President of the Chinese Biological Investigators Society and Chair of the Scientific Advisory Board for the Rothberg Institute for Childhood Diseases. The major thrust of…

View full profile >

Peter Young, Ph.D.

Head of Research and Translational Sciences

Peter Young, Ph.D.

Peter Young is the Head of Research and Translational Sciences at LAM Therapeutics. Dr. Young has over 25 years of experience in target identification, validation, drug discovery and development while holding various executive and management positions at SmithKline Beecham, DuPont Pharmaceuticals, SUGEN, Celera, Genelabs, Affymax and Resverlogix. He has worked in multiple therapeutic areas such as oncology, autoimmune/inflammation, hematology, metabolic and anti-viral disease…

View full profile >
Robert Spiegel

Robert Spiegel, M.D. FACP

Scientific Advisory Board

Robert Spiegel, M.D. FACP

Robert Spiegel joined the LAM Therapeutics Scientific Advisory Board in April, 2013. Dr. Spiegel is the founder of Spiegel Consulting LLC, an independent advisory firm to pharmaceutical and biotechnology companies, and serves as a Senior Advisor to Warburg Pincus and BioPontis Alliance. He retired in 2009 as Chief Medical Officer at Schering-Plough. With 25+ years experience in the pharmaceutical industry, he played…

View full profile >
Brendan Manning

Brendan Manning, Ph.D.

Scientific Advisory Board

Brendan Manning, Ph.D.

Brendan Manning joined the LAM Therapeutics Scientific Advisory Board in May, 2013. Dr. Manning is a Professor in the Department of Genetics and Complex Diseases at the Harvard School of Public Health (HSPH). His doctoral training was in the laboratory of Michael Snyder at Yale University, where he worked basic mechanisms of cell division. Following receipt of his Ph.D. in 2000, Dr. Manning joined the laboratory of Lewis Cantley at Harvard Medical School for his postdoctoral research. During this…

View full profile >
Lawrence Melvin

Lawrence Melvin, Ph.D.

Scientific Advisory Board

Lawrence Melvin, Ph.D.

Larry Melvin joined the LAM Therapeutics Scientific Advisory Board in November, 2013. Dr. Melvin has over 30 years of experience in drug discovery and development with Pfizer, Amgen, Myogen and Gilead. Dr. Melvin has a broad background in medicinal chemistry including the areas of inflammation, respiratory, cardiovascular, central nervous system and antibacterial. He has initiated and led successful drug discovery programs yielding compounds for clinical study and participated in…

View full profile >
Joel S Bader

Joel S. Bader, Ph.D.

Scientific Advisory Board

Joel S. Bader, Ph.D.

Joel Bader joined the LAM Therapeutics Scientific Advisory Board in December, 2014. Dr. Bader is an Associate Professor in the Department of Biomedical Engineering, Johns Hopkins University, and is Interim Director of the High-Throughput Biology Center at the Johns Hopkins School of Medicine. He is a member of the Institute of Computational Medicine and the Institute of Genetic Medicine, and he holds a secondary appointment in the Department of Computer Science at Johns Hopkins…

View full profile >
Joel Dudley

Joel Dudley, Ph.D.

Scientific Advisory Board

Joel Dudley, Ph.D.

Joel Dudley joined the LAM Therapeutics Scientific Advisory Board in December, 2014. Dr. Dudley is Assistant Professor of Genetics and Genomic Sciences and Director of Biomedical Informatics at the Icahn School of Medicine at Mount Sinai in New York City. Dr. Dudley obtained his PhD in Biomedical Informatics from Stanford University School of Medicine, where he developed research in the areas of genomic medicine and translational bioinformatics. Prior to Mount Sinai, he held positions as Co-founder…

View full profile >

Paul Beckett, Ph.D.

Senior Director, Drug Discovery

Paul Beckett, Ph.D.

Paul Beckett joined LAM Therapeutics as Senior Director, Drug Discovery in August, 2013. He is an internationally experienced medicinal chemist and drug discovery leader with a background in emerging biotech/pharmaceutical companies. He played a prominent role in the establishment of British Biotech Pharmaceuticals, the UK’s first publicly traded biotech company, where he contributed extensively to the discovery of the matrix metalloproteinase inhibitor BB-2516 (Marimastat, reached…

View full profile >
Jonathan Rothberg

Jonathan Rothberg, Ph.D.

Board of Directors

Jonathan Rothberg, Ph.D.

Inventor of High-Speed DNA Sequencing. Founder Ion Torrent, RainDance, 454 Life Sciences, ClariFi, and CuraGen.

View full profile >
Gregg Fergus

Gregg Fergus

Board of Directors

Gregg Fergus

Gregg Fergus is the Chief Executive Officer and Chief Commercial Officer of 4Catalyzer, a Guilford, Connecticut-based startup accelerator dedicated to democratizing healthcare and maximizing…

View full profile >
George Rehm

George Rehm

Board of Directors

George Rehm

Founding Partner, aeris CAPITAL AG. Advisor to various family offices.

News

Date
Title / Expand to Read More
View
November 30, 2017

GUILFORD, Conn.—Nov. 30, 2017– LAM Therapeutics (LAM), a 4Catalyzer company, advanced its clinical portfolio with the U.S. Food and Drug Administration (FDA) clearance of LAM’s Investigational New Drug (IND) application for LAM-003 in leukemia patients. LAM-002 has transitioned into Phase 2 as a single agent and in combination with other therapies for treatment of B-cell non-Hodgkin lymphoma (B-NHL). Read more…

View PDF
March 30, 2017

GUILFORD, Conn., March 30, 2017 – LAM Therapeutics, a 4Catalyzer company that develops drugs for cancer and rare diseases, announced that it has closed $58M in Series C financing. 4Catalyzer is Connecticut’s premier biotechnology incubator and has raised over a quarter billion dollars to support its current class of startups.

LAM Therapeutics’ strategy

LAM accelerates drug development by integrating genomics and proteomics technologies with deep learning artificial intelligence (AI) to match clinical drugs to new indications. Read more…

View PDF
February 2, 2016

GUILFORD, Conn. –Feb. 2, 2016– LAM Therapeutics closed a $40 million financing to accelerate the development of therapeutics for the treatment of rare diseases and cancer. LAM Therapeutics is a 4Catalyzer company. 4Catalyzer is Connecticut’s premier biotechnology startup incubator and with this financing has raised a total of a quarter billion dollars to support its current class of startups. Read more…

View PDF
June 06, 2013

Guilford, CT – June 6, 2013 – LAM Therapeutics, the first biopharmaceutical company dedicated to identifying and developing drugs for the treatment of Lymphangioleiomyomatosis (LAM), announced today that it has closed a Series A financing with private investors to launch operations. Proceeds from the financing will be used for identification of clinical stage drugs with potential activity against LAM and to conduct clinical trials. Read more…

View PDF

Contact Us

We would love to hear from you.